OBJECTIVE: Patients with trauma-associated acute lung injury have better outcomes than patients with other clinical risks for lung injury, but the mechanisms behind these improved outcomes are unclear. We sought to compare the clinical and biological features of patients with trauma-associated lung injury with those of patients with other risks for lung injury and to determine whether the improved outcomes of trauma patients reflect their baseline health status or less severe lung injury, or both. DESIGN, SETTING, AND PATIENTS: Analysis of clinical and biological data from 1,451 patients enrolled in two large randomized, controlled trials of ventilator management in acute lung injury. MEASUREMENTS AND MAIN RESULTS: Compared with patients with other clinical risks for lung injury, trauma patients were younger and generally less acutely and chronically ill. Even after adjusting for these baseline differences, trauma patients had significantly lower plasma levels of intercellular adhesion molecule-1, von Willebrand factor antigen, surfactant protein-D, and soluble tumor necrosis factor receptor-1, which are biomarkers of lung epithelial and endothelial injury previously found to be prognostic in acute lung injury. In contrast, markers of acute inflammation, except for interleukin-6, and disordered coagulation were similar in trauma and nontrauma patients. Trauma-associated lung injury patients had a significantly lower odds of death at 90 days, even after adjusting for baseline clinical factors including age, gender, ethnicity, comorbidities, and severity of illness (odds ratio, 0.44; 95% confidence interval, 0.24-0.82; p = .01). CONCLUSIONS: Patients with trauma-associated lung injury are less acutely and chronically ill than other lung injury patients; however, these baseline clinical differences do not adequately explain their improved outcomes. Instead, the better outcomes of the trauma population may be explained, in part, by less severe lung epithelial and endothelial injury. (C) 2007 Lippincott Williams & Wilkins, Inc.
OBJECTIVE:Patients with trauma-associated acute lung injury have better outcomes than patients with other clinical risks for lung injury, but the mechanisms behind these improved outcomes are unclear. We sought to compare the clinical and biological features of patients with trauma-associated lung injury with those of patients with other risks for lung injury and to determine whether the improved outcomes of traumapatients reflect their baseline health status or less severe lung injury, or both. DESIGN, SETTING, AND PATIENTS: Analysis of clinical and biological data from 1,451 patients enrolled in two large randomized, controlled trials of ventilator management in acute lung injury. MEASUREMENTS AND MAIN RESULTS: Compared with patients with other clinical risks for lung injury, traumapatients were younger and generally less acutely and chronically ill. Even after adjusting for these baseline differences, traumapatients had significantly lower plasma levels of intercellular adhesion molecule-1, von Willebrand factor antigen, surfactant protein-D, and soluble tumor necrosis factor receptor-1, which are biomarkers of lung epithelial and endothelial injury previously found to be prognostic in acute lung injury. In contrast, markers of acute inflammation, except for interleukin-6, and disordered coagulation were similar in trauma and nontraumapatients. Trauma-associated lung injurypatients had a significantly lower odds of death at 90 days, even after adjusting for baseline clinical factors including age, gender, ethnicity, comorbidities, and severity of illness (odds ratio, 0.44; 95% confidence interval, 0.24-0.82; p = .01). CONCLUSIONS:Patients with trauma-associated lung injury are less acutely and chronically ill than other lung injurypatients; however, these baseline clinical differences do not adequately explain their improved outcomes. Instead, the better outcomes of the trauma population may be explained, in part, by less severe lung epithelial and endothelial injury. (C) 2007 Lippincott Williams & Wilkins, Inc.
Authors: Polly E Parsons; Michael A Matthay; Lorraine B Ware; Mark D Eisner Journal: Am J Physiol Lung Cell Mol Physiol Date: 2004-10-29 Impact factor: 5.464
Authors: Gordon D Rubenfeld; Ellen Caldwell; Eve Peabody; Jim Weaver; Diane P Martin; Margaret Neff; Eric J Stern; Leonard D Hudson Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245
Authors: Polly E Parsons; Mark D Eisner; B Taylor Thompson; Michael A Matthay; Marek Ancukiewicz; Gordon R Bernard; Arthur P Wheeler Journal: Crit Care Med Date: 2005-01 Impact factor: 7.598
Authors: Renee D Stapleton; Bennet M Wang; Leonard D Hudson; Gordon D Rubenfeld; Ellen S Caldwell; Kenneth P Steinberg Journal: Chest Date: 2005-08 Impact factor: 9.410
Authors: Michael A Matthay; B Taylor Thompson; Elizabeth J Read; David H McKenna; Kathleen D Liu; Carolyn S Calfee; Jae Woo Lee Journal: Chest Date: 2010-10 Impact factor: 9.410
Authors: Harold R Collard; Carolyn S Calfee; Paul J Wolters; Jin Woo Song; Sang-Bum Hong; Sandra Brady; Akitoshi Ishizaka; Kirk D Jones; Talmadge E King; Michael A Matthay; Dong Soon Kim Journal: Am J Physiol Lung Cell Mol Physiol Date: 2010-04-23 Impact factor: 5.464
Authors: Mark E Mikkelsen; Chirag V Shah; Arnaud Scherpereel; Paul N Lanken; Philippe Lassalle; Scarlett L Bellamy; A Russell Localio; Steven M Albelda; Nuala J Meyer; Jason D Christie Journal: J Crit Care Date: 2011-09-29 Impact factor: 3.425
Authors: Chau-Chyun Sheu; Michelle N Gong; Rihong Zhai; Feng Chen; Ednan K Bajwa; Peter F Clardy; Diana C Gallagher; B Taylor Thompson; David C Christiani Journal: Chest Date: 2010-05-27 Impact factor: 9.410
Authors: Carolyn S Calfee; Lorraine B Ware; David V Glidden; Mark D Eisner; Polly E Parsons; B Taylor Thompson; Michael A Matthay Journal: Crit Care Med Date: 2011-04 Impact factor: 7.598
Authors: Carolyn S Calfee; Kevin Delucchi; Polly E Parsons; B Taylor Thompson; Lorraine B Ware; Michael A Matthay Journal: Lancet Respir Med Date: 2014-05-19 Impact factor: 30.700